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This study was conducted in order to investigate the implications of the R72P polymorphism in the TP53 gene in
breast cancer risk. The enlightenment of this matter might provide a piece of information about the potential
implications of this polymorphism in patient risk. A meta-analysis was conducted considering a large sample size
from studies with conflicting results on the R72P polymorphism in breast cancer patients. Relevant studies were
selected from PubMed and SciELO databases for data extraction and statistical analysis. Database was built according to
the continent and considering the genotype frequencies, sample size and genotyping methodology. The dominant
models (RR vs RP + PP and RR + RP vs. PP), homozygous (RR vs. PP), heterozygous (RR vs. RP and RP vs. PP) and
the allele (R vs. P) were used. Genotype frequencies were summarized and evaluated by χ2 test of heterogeneity
in 2×2 contingency tables with 95% CIs. Odds Ratios (OR) were calculated with a fixed-effect model (Mantel-Haenszel) or
a random-effect model (DerSimonian-Laird) if the studies were considered homogeneous (P > 0.05) or heterogeneous
(P < 0.05), respectively, using BioEstat® 5.0 software. Supported by a large sample size composed by 25,629 cases and
26,633 controls from 41 studies, we found significant association between the R72P polymorphism in the TP53 gene and
the breast cancer risk. The overall data shows an increased risk due to the P allele dominant model, but not in Asia where
the risk was associated with the R allele and R dominant model.
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The R72P polymorphism in the TP53 gene results of the
transversion G→ C in the second position of the codon
72 at exon 4. Both the polymorphic alleles vary among
ethnic groups (Dokianakis et al. 2000) and geographic
location, where the P allele is more frequent toward the
equador line purportedly as a protective factor against
UV rays (Damin et al. 2006; Olivier et al. 2002). P53
variant proteins have an arginine (R) or a proline (P)
encoded by codon 72, which differ in structure and func-
tion, specially concerning cell cycle progress (Chang-
Claude et al. 2009; Schmidt et al. 2009; Thomas et al.
1999; Petitjean et al. 2007; Dumont et al. 2003).* Correspondence: marciocmed@gmail.com
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in any medium, provided the original work is pBreast cancer is an heterogeneous sporadic or heredi-
tary disease (Lima et al. 2006). The hereditary syndrome
affects 10% of patients, of which 5% has high penetrance
mutations in genes like BRAC1 and BRCA2 (BRCA1/2)
(Pinto et al. 2007). BRCA1/2 and TP53 are susceptibility
genes that confer high-risk of breast cancer (Oluwagbemiga
et al. 2012). Evidences that the R72P polymorphisms in the
TP53 gene can differently promote the transcription of
BRAC1/2 have widely supported studies on R72P role in
breast tumorigenesis (Sinilnikova et al. 2009; Lum et al.
2008; Osorio et al. 2008; Gochhait et al. 2007; Cavallone
et al. 2008; Baynes et al. 2007; Tommiska et al. 2005;
Martin et al. 2003; Huang et al. 2003), e.g., (1) the P
variant binds greater to transcriptional machinery
(Thomas et al. 1999) and thus shows higher rates of
G1 arrest than the R variant protein (Petitjean et al.
2007; Gochhait et al. 2007); (2) the decreased effi-
ciency of the P variant at triggering apoptosis (Chang-
Claude et al. 2009; Dumont et al. 2003), mainly due to
its decreased ubiquination by MDM2 (Sinilnikova et al.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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et al. 2010) and to its increased efficiency to bind the
inhibitor of apoptosis-stimulating protein of p53 (iASPP)
(Schmidt et al. 2009; Bergamaschi et al. 2006).
In the present study, a meta-analysis was conducted
considering a large sample size from studies with con-
flicting results on the R72P polymorphism in breast
cancer patients. The enlightenment of this matter might
provide a piece of information about the potential implica-
tions of this polymorphism in patient’s risk.
Material and methods
Identification and eligibility of relevant studies
A literature search was conducted in SciELO (Scientific
Eletronic Library Online) and PubMed databases by using
the keywords: p53, polymorphism, breast cancer. Additional
studies were searched among the references surveyed in
the databases. Eligible studies were selected regardless of
sample size, but had to meet the following criteria of inclu-
sion: (a) the studies were published from 2002 to 2012; (b)
the association between the R72P polymorphism and breast
cancer were investigated; (c) the studies were case–control
design; (d) genotyping was carried out by molecular biology
methods, such as PCR, RFLP-PCR and DNA sequencing;
(e) the reference was published in English; (f) histological
confirmation of breast cancer diagnosis was performed;
and (g) the genotype distributions were available forFigure 1 Flow diagram of the studies evaluated for meta-analysis.estimating odds ratios (OR) and 95% confidence inter-
vals (CI).
Data extraction
Two investigators independently extracted data and
reached a consensus on all of the items. A third inves-
tigator took part of data extraction in case of disagree-
ment in any of the items. The data extracted regarded
country of origin, first author, and year of publication,
number of cases and controls, and genotype frequencies.
Statistical analysis
In the current meta-analysis, the dominant models (RR vs
RP + PP and RR + RP vs. PP), homozygous (RR vs. PP),
heterozygous (RR vs. RP and RP vs. PP) and the allele
(R vs. P) were used. Genotype frequencies were summa-
rized and evaluated by χ2 test of heterogeneity in 2×2
contingency tables with 95% CIs (Böhning et al. 2002).
Odds Ratios (OR) were calculated with a fixed-effect
model (Mantel-Haenszel) or a random-effect model
(DerSimonian-Laird) if the studies were considered
homogeneous (P > 0.05) or heterogeneous (P < 0.05),
respectively. The OR and their corresponding 95% CI
were used to test the association between the 72 codon
polymorphism and breast cancer. All analyses were per-
formed with BioEstat® 5.0 software. To estimate a combined
effect, OR were calculated for both fixed and random effect
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weights for the studies (Li et al. 2012; Conn et al. 2012;
Manning et al. 2011; Higgins et al. 2008).Results and discussion
Study inclusion and characteristics
A total of 492 studies were screened, of which three
were found in both PubMed and SciELO. From the 489
studies screened, 218 were published before 2002 and
20 were reviews or published in another language than
English, or both. The remaining 271 records were assessed
for eligibility and 41 fulfilled the criteria of inclusion
(Figure 1). From the selected studies, a database was
built considering the continent, genotype frequencies,
sample size and genotype methodology. All together,
the 41 studies that met the inclusion criteria and were
identified as eligible article, yielding 25,629 cases and
26,633 controls.
In the last 10 years, eligible studies on R72P polymorph-
ism in the TP53 gene in breast cancer were mostly from
Europe with 19 articles, followed by Asia, America and
Africa with 14, 6 and 2, respectively. Subject’s age was
collected, when available, showing that mean age ofFigure 2 Meta-analysis evaluation of the dominant model RR + RP vs.patients was 51.9 y.o. and of control subjects 48.1 y.o.
The genotyping for p53 codon 72 polymorphism was
performed using Polymerase Chain Reaction (PCR), Allele-
Specific PCR (AS-PCR), Amplifluor®, GoldenGate® Geno-
typing Assay (GGA), PCR-Denaturing Gradient Gel
Electrophoresis (PCR-DGGE), PCR-Restriction Fragment
Length Polymorphism (PCR-RFLP), sequencing and
Taqman PCR. Breast cancer patients and controls sub-
jects were mainly heterozygous in Asia (50.1%; 48.0%)
and Africa (43.9%; 49.7%), while the RR homozygous
was predominant in America (53.6%; 54.5%) and Europe
(54.1%; 53.4%). The R allele was predominant in breast
cancer patients from America and Europe (73.3%, each),
Africa (63.2%) and Asia (58.3%).
Quantitative synthesis
The dominant models RR + RP vs. PP and RR vs. RP +
PP had OR calculated using a random-effect model. No
association between breast cancer risk and the dominant
model RR + RP vs. PP (OR = 1.09; 95% CI 0.98-1.22) was
found (Figure 2 and Table 1). By the other hand, our
findings for RR vs. RP + PP (OR = 1.11; 95% CI 1.02-1.21)
showed a markedly increased risk of breast cancer associ-
ated with the RP and PP genotypes, considering the PPP.
Table 1 Meta-analysis of the R72P polymorphism of the gene TP53 on breast cancer
Studies/continent No. of case/
control
RR + RP vs. PP RR vs. RP + PP R vs. P
OR (95% CI) OR (95% CI) OR (95% CI)
Africa Σ=189/181 1.13 (0.64-2.01) 1.40 (0.91-2.15) 1.16 (0.86-1.56)
Trifa et al., 2010 159/132 1.19 (0.65-2.19) 1.21 (0.75-1.96) 1.15 (0.83-1.61)
Mabrouk et al., 2003 30/49 0.78 (0.18-3.40) 2.32 (0.93-5.78) 1.59 (0.78-3.27)
America Σ=6,483/8,011 0.99 (0.87-1.12) 1.05 (0.88-1.26) 0.98 (0.92-1.02)
Damin et al., 2006 118/202 2.05 (0.83-5.09) 2.22 (1.40-3.53) 1.79 (1.25-2.55)
Aoki et al., 2009 72/90 1.78 (0.48-6.60) 2.47 (1.31-4.66) 1.85 (1.14-3.00)
Gaudet et al., 2008 578/390 1.11 (0.70-1.76) 0.78 (0.61-1.01) 0.88 (0.71-1.08)
Cox et al., 2007 1,477/2,224 0.83 (0.63-1.08) 0.92 (0.81-1.05) 0.92 (0.83-1.02)
Garcia-Closas et al. 2007 2,585/3,251 0.92 (0.75-1.12) 0.94 (0.84-1.04) 0.95 (0.87-1.03)
Sprague et al., 2007 1,653/1,854 1.16 (0.89-1.52) 1.00 (0.87-1.14) 1.02 (0.92-1.14)
Asia Σ=2,570/2,833 1.21 (0.89-1.64) 1.08 (0.89-1.32) *1.09 (1.01-1.17)
Lum et al., 2008 393/80 0.69 (0.37-1.30) 0.64 (0.39-1.06) 0.73 (0.51-1.03)
Gochhait et al., 2007 243/333 1.66 (1.12-2.46) 1.85 (1.28-2.67) 1.56 (1.23-1.92)
Huang et al., 2003 200/282 0.54 (0.32-0.92) 0.70 (0.48-1.02) 0.72 (0.55-0.93)
Ma et al. 2006 404/472 1.14 (0.82-1.59) 1.25 (0.95-1.66) 1.16 (0.96-1.40)
Rajkumar et al., 2008 250/500 1.27 (0.89-1. 80) 0.97 (0.69-1.37) 1.08 (0.87-1.34)
Li et al., 2002 28/50 1.38 (0.48-3.99) 2.54 (0.93-6.94) 1.68 (0.87-3.27)
Alawadi et al., 2011 288/188 6.12 (2.66-14.08) 1.08 (0.71-1.63) 1.31 (1.00-1.71)
Suresh et al., 2011 35/37 2.28 (0.59-8.91) 0.95 (0.35-2.57) 1.21 (0.62-2.34)
Kazemi et al., 2009 42/57 0.05 (0.003-0.89) 0.65 (0.23-1.84) 0.65 (0.37-1.15)
Singh et al., 2008 104/105 0.91 (0.40-2.06) 2.26 (1.21-3.85) 1.42 (0.96-2.11)
Khadang et al., 2007 221/205 1.60 (0.95-2.68) 1.04 (0.70-1.54) 1.17 (0.89-1.54)
Siddique et al., 2005 94/265 0.62 (0.34-1.12) 0.92 (0.57-1.49) 0.83 (0.59-1.16)
Noma et al., 2004 191/218 0.93 (0.54-1.60) 0.92 (0.62-1.35) 0.82 (0.61-1.10)
Katiyar et al., 2003 77/41 2.79 (0.93-8.39) 1.22 (0.51-2.95) 1.38 (0.80-2.36)
Europe Σ=16,387/15,608 1.03 (0.95-11.25) 1.13 (1.00-1.27) 1.02 (0.99-1.06)
Sinilnikova et al., 2009 3,959/3,052 0.97 (0.80-1.16) 1.01 (0.92-1.11) 1.00 (0.93-1.08)
Cavallone et al., 2008 157/112 1.29 (0.52-3.21) 1.00 (0.62-1.63) 1.04 (0.71-1.53)
Baynes et al., 2007 2,023/2,197 1.04 (0.82-1.30) 1.05 (0.93-1.18) 1.04 (0.95-1.14)
Tommiska et al., 2005 1,551/733 1.02 (0.72-1.43) 0.93 (0.78-1.11) 0.96 (0.83-1.10)
Akkiprik et al. 2009 95/108 0.39 (0.14-1.12) 1.38 (0.78-2.42) 1.02 (0.65-1.91)
Kara et al., 2010 204/192 1.48 (0.73-3.00) 1.45 (0.98-2.15) 1.34 (0.99-1.81)
Bisof et al., 2010 95/107 0.48 (0.22-1.04) 0.48 (0.27-0.87) 0.58 (0.39-0.86)
Denisov et al., 2009 297/275 1.28 (0.73-2.23) 0.87 (0.62-1.20) 0.96 (0.75-1.25)
Henrıquez-Hernandez et al. 2009 135/295 1.60 (0.72-3.54) 0.90 (0.60-1.36) 1.03 (0.74-1.43)
Costa et al., 2008 248/646 0.81 (0.49-1.32) 0.86 (0.64-1.16) 0.87 (0.69-1.10)
Buyru et al., 2007 115/63 1.44 (0.58-3.57) 1.77 (0.96-3.29) 1.52 (0.96-2.43)
Johnson et al., 2007 472/2,462 1.17 (0.79-1.74) 0.98 (0.80-1.19) 1.01 (0.87-1.19)
Schmidt et al. 2007 5,191/3,834 1.01 (0.86-1.18) 1.05 (0.96-1.14) 1.03 (0.96-1.10)
Kalemi et al., 2005 42/51 2.52 (0.69-9.26) 6.35 (2.54-15.84) 3.29 (1.73-6.25)
Ohayon et al., 2005 132/167 4.86 (1.52-15.53) 4.29 (4.68-6.96) 3.10 (2.10-4.56)
Menzel et al., 2004 475/302 1.64 (0.97-2.76) 1.25 (0.94-1.67) 1.27 (1.01-1.60)
Buyru et al., 2003 115/76 1.61 (0.69-3.73) 3.23 (1.7-6.00) 2.09 (1.36-3.22)
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Table 1 Meta-analysis of the R72P polymorphism of the gene TP53 on breast cancer (Continued)
Suspitsin et al., 2003 529/393 0.86 (0.52-1.41) 1.04 (0.80-1.35) 1.00 (0.81-1.23)
Wang-Gohrke et al., 2002 552/543 0.82 (0.53-1.26) 0.85 (0.67-1.07) 0.87 (0.72-1.05)
Overall 25,629/26,633 1.09 (0.98-1.22) *1.11 (1.02-1.21) 1.02 (1.00-1.05)
Heterogeneity χ2 = 80.19 χ2 = 146.02 χ2 = 6.54
P = 0.0002 P<0.0001 P = 0.088
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with our results, the PP genotype was previously asso-
ciated with higher risk for breast cancer (Huang et al.
2003; Rajkumar et al. 2008). Among unselected breast
cancer patients, the PP genotype also predicted poor
survival and a 2-fold increased risk of death (Tommiska
et al. 2005).
The P allele has been associated with earlier breast
cancer onset in BRCA1/2 mutation carriers (Tommiska
et al. 2005; Martin et al. 2003), probably due to pene-
trance modification in BRCA1 (Martin et al. 2003) and
to the lower ability of the P variant to induce apoptosis
in genotoxic stress (Chang-Claude et al. 2009; Dumont
et al. 2003). However, most of the studies selected for
this meta-analysis have failed to detect any implication
of R72P to breast cancer risk. Among most of theFigure 3 Meta-analysis evaluation of the dominant model RR vs. RP +selected references, no risk modification by R72P was
found in wild type BRCA1/2 and mutation carriers, even
if the age of diagnosis or tumor stage were regarded
(Sinilnikova et al. 2009; Lum et al. 2008; Cavallone et al.
2008; Baynes et al. 2007; Tommiska et al. 2005). Our
overall data showed an association of risk increase with
PP genotype, but not with the alleles alone (R vs. P; OR =
1.02; 95% CI 1.00-1.05), as described in Table 1. The lack
of implication concerning P allele alone might be ex-
plained by the R allele in the heterozygous, because the
R variant may act in a codominant mode to decrease
breast cancer risk and to detain the onset in sporadic
cases (Lum et al. 2008). Although our overall data show
no association with the alleles alone, the analysis of 2,570
cases and 2,833 controls from Asia demonstrated a mark-
edly increase of the R allele frequency in breast cancerPP.
Table 2 Meta-analysis of the R72P polymorphism of the gene TP53 on breast cancer, by pooling data per continent
RR vs. RP RR vs. PP RP vs. PP RR+RP vs. PP RR vs. RP+PP
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Africa 1.41 (0.90-2.22) 1.30 (0.69-2.44) 0.99 (0.54-1.83) 1.05 (0.6-1.86) 1.32 (0.86-2.01)
America 1.04 (0.87-1.23) 1.04 (0.82-1.33) 1.01 (0.88-1.16) 0.98 (0.86-1.11) 0.96 (0.90-1.03)
Asia 1.05 (0.88-1.26) 1.24 (0.87-1.78) 1.15 (0.85-1.57) *1.23 (1.07-1.41) 1.04 (0.93-1.17)
Europe 1.09 (0.97-1.22) 1.10 (0.93-1.31) 1.01 (0.92-1.11) 1.04 (0.95-1.13) 1.03 (0.98-1.08)
Overall 1.01 (0.97-1.04) 1.05 (0.99-1.12) 1.05 (0.99-1.12) 1.06 (0.99-1.12) 1.05 (0.98-1.05)
Heterogeneity χ2 = 3.91 χ2 = 5.42 χ2 = 5.78 χ2 = 6.15 χ2 = 4.53
P = 0.27 P = 0.14 P = 0.12 P = 0.10 P = 0.21
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in Table 1.
Ethnic and geographical nonspecific factors, further to
allele frequencies variations in different health popula-
tions, have been argued as the reason to the controver-
sial data on R72P role in breast cancer (Dokianakis et al.
2000; Lum et al. 2008; Huang et al. 2003). Worth of note
in this regard is that, in our meta-analysis, R allele was
the most frequent in patients and control subjects, featur-
ing the allele frequencies as a potential ethnic or geograph-
ical risk factor. By pooling all studies per continent, we
performed the analyses of the dominant models and the
genotypes using the fixed-effect model. Our overall re-
sults showed no association of the R72P polymorphism
with breast cancer, but Asian patients had an increased
risk associated with the dominant model RR + RP vs. PP
(OR = 1.23; 95% CI 1.07-1.41), as described in Table 2.
These remarkable data concerning RR + RP genotypes
and R allele in Asia are in agreement with the reports
that R variant increased breast risk in patients from
China (Weston & Godbold 1997; Li et al. 2002) and India
(Gochhait et al. 2007). In contrast, previous meta-analysis
designed studies failed to correlate the R72P polymorph-
ism with breast cancer (Ma et al. 2006; Zhuo et al. 2009),
even when subjects were stratified by ethnicity or source
of controls (Ma et al. 2011).
In conclusion, we found significant association between
the R72P polymorphism in the TP53 gene and the breast
cancer risk. The overall data showed an increased risk due
to the P allele dominant model, but not in Asia where the
risk was associated with the R allele and R dominant
model. The present meta-analysis is supported by a large
sample size composed by 25,629 cases and 26,633 controls
from 41 studies.
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